HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

NCT01683188 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Stopped slow accrual led to early closure.

Conditions

Metastatic Melanoma

Interventions

DRUG: vemurafenib + HD IL-2

Sponsor

Clinigen, Inc.

Collaborators

[object Object]